: Biological nanoparticles, such as proteins and extracellular vesicles, are rapidly growing as nanobased drug-delivery agents due to their biocompatibility, high loading efficiency, and bioavailability. However, most of the candidates emerging preclinically hardly confirm their potential when entering clinical trials. Among other reasons, this is due to the low control of synthesis processes and the limited characterization of their potential immunoreactivity profiles. Here, we propose a combined method that allow us to fully characterize H-ferritin nanoparticles' immunoreactivity during their production, purification, endotoxin removal, and drug loading. H-Ferritin is an extremely interesting nanocage that is being under evaluation for cancer therapy due to its innate cancer tropism, favorable size, and high stability. However, being a recombinant protein, its immunoreactivity should be carefully evaluated preclinically to enable further clinical translation. Surprisingly, this aspect is often underestimated by the scientific community. By measuring proinflammatory cytokine release as a function of endotoxin content, we found that even removing all pyrogenic contaminants from the nanocage, a mild immunoreactivity was still left. When we further purified H-ferritin by loading doxorubicin through a highly standardized loading method, proinflammatory cytokine release was eliminated. This confirmed the safety of H-ferritin nanocages to be used for drug delivery in cancer therapy. Our approach demonstrated that when evaluating the safety of nanodrugs, a combined analysis of acute toxicity and immunoreactivity is necessary to guarantee the safety of newly developed products and to unveil their real translational potential.

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs / L. Sitia, V. Galbiati, A. Bonizzi, M. Sevieri, M. Truffi, M. Pinori, E. Corsini, M. Marinovich, F. Corsi, S. Mazzucchelli. - In: BIOCONJUGATE CHEMISTRY. - ISSN 1520-4812. - (2023), pp. 1-11. [Epub ahead of print] [10.1021/acs.bioconjchem.3c00038]

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs

L. Sitia
Primo
;
V. Galbiati
Secondo
;
M. Sevieri;E. Corsini;M. Marinovich;F. Corsi
Penultimo
;
S. Mazzucchelli
Ultimo
2023

Abstract

: Biological nanoparticles, such as proteins and extracellular vesicles, are rapidly growing as nanobased drug-delivery agents due to their biocompatibility, high loading efficiency, and bioavailability. However, most of the candidates emerging preclinically hardly confirm their potential when entering clinical trials. Among other reasons, this is due to the low control of synthesis processes and the limited characterization of their potential immunoreactivity profiles. Here, we propose a combined method that allow us to fully characterize H-ferritin nanoparticles' immunoreactivity during their production, purification, endotoxin removal, and drug loading. H-Ferritin is an extremely interesting nanocage that is being under evaluation for cancer therapy due to its innate cancer tropism, favorable size, and high stability. However, being a recombinant protein, its immunoreactivity should be carefully evaluated preclinically to enable further clinical translation. Surprisingly, this aspect is often underestimated by the scientific community. By measuring proinflammatory cytokine release as a function of endotoxin content, we found that even removing all pyrogenic contaminants from the nanocage, a mild immunoreactivity was still left. When we further purified H-ferritin by loading doxorubicin through a highly standardized loading method, proinflammatory cytokine release was eliminated. This confirmed the safety of H-ferritin nanocages to be used for drug delivery in cancer therapy. Our approach demonstrated that when evaluating the safety of nanodrugs, a combined analysis of acute toxicity and immunoreactivity is necessary to guarantee the safety of newly developed products and to unveil their real translational potential.
Settore BIO/10 - Biochimica
Settore MED/18 - Chirurgia Generale
   INVESTIGATION OF THE ROLE OF CYTOCHROME C3 ON LOCALISED PROTON FLOW PATHWAYS LEADING TO THE ATP SYNTHASE
   PRAXIS XXI/BPD/20172/99
   Fundação para a Ciência e a Tecnologia, I.P.
   POCTI
   PRAXIS XXI/BPD/20172/99
2023
24-feb-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
acs.bioconjchem.3c00038.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 4.63 MB
Formato Adobe PDF
4.63 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/961616
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact